Journal
CLINICAL GENITOURINARY CANCER
Volume 14, Issue 4, Pages 265-270Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2015.12.030
Keywords
Biomarkers; Drug resistance; Neoplasms metastasis; Prostatic neoplasms; Receptors androgen; Taxoids
Categories
Funding
- Instituto de Salud Carlos III Subdireccion General de Evaluacion y Fomento de la Investigacion [PI12/01226, PI15/00676]
- Hospital Clinic de Barcelona (Premi Fi de Residencia Emili Letang)
- Sanofi
Ask authors/readers for more resources
Prostate cancer is a molecularly heterogeneous disease, and mechanisms of action of taxanes and potential mechanisms of resistance are not clearly defined. Taxanes are microtubule-stabilizing agents resulting in the slowing or blocking of mitosis at the metaphase-anaphase transition and induction of apoptotic cell death. Taxanes also can inhibit androgen receptor pathway. To date, several factors have been associated with taxane resistance, including alterations in tubulin, the effect of drug efflux pumps, and the dysfunctional regulation of signaling pathways that may be involved in resistance to therapy. Preclinical and clinical data support the distinct activity of cabazitaxel in prostate cancer that may overcome resistance to prior taxanes or hormonal therapies. It is challenging to define the most adequate therapeutic sequence for each patient. Moreover, the identification of molecular markers of resistance may help to select patients for specific therapies. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available